drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Antibody–drug conjugate (human IgG1 mAb targeting Nectin-4) linked to the cytotoxic payload monomethyl auristatin E (MMAE). After Nectin-4 binding and internalization, MMAE is released to inhibit tubulin polymerization, inducing G2/M arrest and apoptosis; given 1.25 mg/kg IV on days 1, 8, and 15 of 28-day cycles.
nci_thesaurus_concept_id
C114500
nci_thesaurus_definition
An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.
drug_mesh_term
enfortumab vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Enfortumab vedotin is a human IgG1 monoclonal antibody targeting Nectin-4 conjugated via a protease-cleavable linker to the cytotoxic payload monomethyl auristatin E (MMAE). After binding Nectin-4 on tumor cells and internalization, the linker is cleaved to release MMAE, which inhibits tubulin polymerization, causing G2/M cell-cycle arrest and apoptotic cell death; a local bystander effect may occur.
drug_name
Enfortumab vedotin
nct_id_drug_ref
NCT05915351